Bone Abstracts

Recent studies indicate a potential importance of the antioxidant α-tocopherol for bone and the development of sarcopenia. No longitudinal clinical fracture studies have been performed. We aimed to determine whether α-tocopherol intake or serum concentrations are associated with fracture risk in older women and men. We used data from two community-based cohorts, the Swedish Mammography Cohort (SMC; 61 433 women) and the Uppsala Longitudinal Study of Adult Men (ULSAM;...

Introduction: Micro-RNAs (miRNAs) are important post-transcriptional regulators. By binding to complementary RNA strands, they affect mRNA levels and/or mRNA translation. We have previously identified ~90 miRNAs with significant expression levels, with a subset of miRNAs exhibiting interindividual and/or gender differences in expression. In the present project, we have investigated the impact of treatment of parathyroid hormone (PTH) and dexamethasone (DEXA) on global miRNA ex...

Abstract: Osteogenesis imperfecta, also known as ‘brittle bone disease’, is a heterogeneous disorder of connective tissue generally caused by dominant mutations in the genes COL1A1 and COL1A2, encoding the α1 and α2 chains of type I (pro)collagen. Symptomatic patients are usually prescribed bisphosphonates, but this treatment is neither curative nor sufficient. A promising field is gene silencing through RNA interference. In this study, small interfering RN...

Infantile malignant osteopetrosis (IMO) is a rare, lethal, recessive disorder characterized by dysfunctional osteoclasts. TCIRG1, encoding the osteoclast V-ATPase, is mutated in 50% of IMO patients. We have previously shown that the resorptive function in osteoclasts derived from IMO patients can be restored in vitro by expressing TCIRG1 using a lentiviral vector. In this study, we aim to investigate the cellular response to vector-derived TCIRG1 expression and to det...

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the primary efficacy analysis of the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk compared with placebo in postmenopausal women with osteoporosis. Pre-specified subgroup analyses evaluated the efficacy of ODN in patient subgroups.Women aged ≥65 years, without baseline radiographic...